Takao Yamori

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10757564/publications.pdf

Version: 2024-02-01

170	9,406	44042	45285
papers	citations	48 h-index	90 g-index

193	193	193	13786
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. Journal of Cell Biology, 2002, 158, 227-233.	2.3	859
2	Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene, 1999, 18, 813-822.	2.6	625
3	Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor. Journal of the National Cancer Institute, 2006, 98, 545-556.	3.0	369
4	Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer, 2001, 92, 1085-1091.	2.0	267
5	Lysophosphatidic Acid and Autotaxin Stimulate Cell Motility of Neoplastic and Non-neoplastic Cells through LPA1. Journal of Biological Chemistry, 2004, 279, 17634-17639.	1.6	251
6	Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting. Science Translational Medicine, 2011, 3, 64ra2.	5.8	231
7	Autotaxin Is Overexpressed in Glioblastoma Multiforme and Contributes to Cell Motility of Glioblastoma by Converting Lysophosphatidylcholine TO Lysophosphatidic Acid. Journal of Biological Chemistry, 2006, 281, 17492-17500.	1.6	206
8	Effect on Tumor Cells of Blocking Survival Response to Glucose Deprivation. Journal of the National Cancer Institute, 2004, 96, 1300-1310.	3.0	205
9	Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition. Cancer Research, 2013, 73, 3087-3096.	0.4	194
10	An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Research, 2002, 62, 1139-47.	0.4	190
11	Blockade of the Stromal Cellâ€“Derived Factor-1/CXCR4 Axis Attenuates In vivo Tumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factorâ€“Independent Manner. Cancer Research, 2005, 65, 5864-5871.	0.4	178
12	Pladienolides, New Substances from Culture of Streptomyces platensis Mer-11107 III. In Vitro and In Vivo Antitumor Activities. Journal of Antibiotics, 2004, 57, 188-196.	1.0	172
13	Insulin and Insulin-like Growth Factor 1 Stimulate Proliferation of Metastatic Variants of Colon Carcinoma 26. Japanese Journal of Cancer Research, 1989, 80, 51-58.	1.7	155
14	Antibacterial and antiproliferative activity of cationic fullerene derivatives. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4395-4397.	1.0	141
15	Phosphatidylinositol 3â€kinase inhibitors: promising drug candidates for cancer therapy. Cancer Science, 2008, 99, 1734-1740.	1.7	140
16	Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemotherapy and Pharmacology, 2003, 52, 74-79.	1.1	137
17	ZSTK474 is an ATPâ€competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Science, 2007, 98, 1638-1642.	1.7	131
18	Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: In silico and Biological Evaluations. Cancer Research, 2010, 70, 4982-4994.	0.4	108

#	Article	IF	Citations
19	Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochemical and Biophysical Research Communications, 2003, 309, 18-25.	1.0	107
20	Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors. Current Medicinal Chemistry, 2009, 16, 2839-2854.	1.2	105
21	Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb. Clinical Cancer Research, 2012, 18, 1268-1280.	3.2	105
22	p53-Defective Tumors With a Functional Apoptosome-Mediated Pathway: A New Therapeutic Target. Journal of the National Cancer Institute, 2005, 97, 765-777.	3.0	101
23	Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer. Clinical Cancer Research, 2011, 17, 2260-2269.	3.2	101
24	In Vitro Cytotoxicity of the Protoberberine-Type Alkaloids. Journal of Natural Products, 2001, 64, 896-898.	1.5	98
25	TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling. Cell Discovery, 2018, 4, 1.	3.1	97
26	Leptosins isolated from marine fungus Leptoshaeria species inhibit DNA topoisomerases I and/or II and induce apoptosis by inactivation of Akt/protein kinase B. Cancer Science, 2005, 96, 816-824.	1.7	78
27	Total Synthesis and Biological Assessment of (â˜)â€Exiguolide and Analogues. Chemistry - A European Journal, 2011, 17, 2678-2688.	1.7	76
28	Leptosins Mâ€“N1, cytotoxic metabolites from a Leptosphaeria species separated from a marine alga. Structure determination and biological activities. Tetrahedron, 2002, 58, 479-487.	1.0	75
29	Abdominal Infection Suppresses the Number and Activity of Intrahepatic Natural Killer Cells and Promotes Tumor Growth in a Murine Liver Metastasis Model. Annals of Surgical Oncology, 2016, 23, 257-265.	0.7	75
30	SKI and MEL1 Cooperate to Inhibit Transforming Growth Factor-Î² Signal in Gastric Cancer Cells. Journal of Biological Chemistry, 2009, 284, 3334-3344.	1.6	74
31	Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide. Biochemical Pharmacology, 2003, 66, 481-487.	2.0	73
32	Urukthapelstatin A, a Novel Cytotoxic Substance from Marine-derived Mechercharimyces asporophorigenens YM11-542. Journal of Antibiotics, 2007, 60, 251-255.	1.0	72
33	Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. European Journal of Cancer, 2010, 46, 1111-1121.	1.3	71
34	Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2909-2922.	2.9	70
35	Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Molecular Cancer Therapeutics, 2005, 4, 399-412.	1.9	68
36	AMF-26, a Novel Inhibitor of the Golgi System, Targeting ADP-ribosylation Factor 1 (Arf1) with Potential for Cancer Therapy. Journal of Biological Chemistry, 2012, 287, 3885-3897.	1.6	68

#	Article	IF	Citations
37	Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. European Journal of Cancer, 2009, 45, 857-865.	1.3	66
38	Isolation of a novel gene on 8p21.3â€“22 whose expression is reduced significantly in human colorectal cancers with liver metastasis. Genes Chromosomes and Cancer, 2000, 29, 9-15.	1.5	63
39	ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacologica Sinica, 2010, 31, 1189-1197.	2.8	62
40	Total Synthesis of the Bicyclic Depsipeptide HDAC Inhibitors Spiruchostatins A and B, 5â€²â€²â€epiâ€Spiruchostatin B, FK228 (FR901228) and Preliminary Evaluation of Their Biological Activity. Chemistry - A European Journal, 2009, 15, 11174-11186.	1.7	61
41	Structure-activity relationships of quaternary protoberberine alkaloids having an antimalarial activity. European Journal of Medicinal Chemistry, 1999, 34, 1077-1083.	2.6	60
42	Anti-tumor Efficacy of Paclitaxel against Human Lung Cancer Xenografts. Japanese Journal of Cancer Research, 1997, 88, 1205-1210.	1.7	59
43	Yakuâ€™amides A and B, Cytotoxic Linear Peptides Rich in Dehydroamino Acids from the Marine Sponge Ceratopsion sp.. Journal of the American Chemical Society, 2010, 132, 17692-17694.	6.6	59
44	Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase. Biological and Pharmaceutical Bulletin, 2009, 32, 297-300.	0.6	57
45	JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorganic and Medicinal Chemistry, 2012, 20, 1947-1951.	1.4	56
46	Synthesis and biological relationships of 3â€²,6-substituted 2-phenyl-4-quinolone-3-carboxylic acid derivatives as antimitotic agents. Bioorganic and Medicinal Chemistry, 2005, 13, 265-275.	1.4	53
47	Sesquiterpenoids and Flavonoids from the Aerial Parts of Tithonia diversifolia and Their Cytotoxic Activity. Chemical and Pharmaceutical Bulletin, 2007, 55, 1240-1244.	0.6	52
48	Selective sensitivity to wasabi-derived 6-(methylsulfinyl)hexyl isothiocyanate of human breast cancer and melanoma cell lines studied in vitro. Cancer Detection and Prevention, 2005, 29, 155-160.	2.1	50
49	Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1/2 inhibitor. Cancer Science, 2007, 98, 1809-1816.	1.7	50
50	Structural Revision of Sulfated Polysaccharide B-1 Isolated from a Marine Pseudomonas Species and Its Cytotoxic Activity Against Human Cancer Cell Lines. Marine Biotechnology, 2003, 5, 13-19.	1.1	48
51	Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochemical Pharmacology, 2008, 75, 360-368.	2.0	47
52	Antiproliferative and Antiangiogenic Activities of Smenospongine, a Marine Sponge Sesquiterpene Aminoquinone. Marine Drugs, 2011, 9, 154-161.	2.2	47
53	In Vitro Antitumor Activity of Stellettin B, a Triterpene from Marine Sponge Jaspis stellifera, on Human Glioblastoma Cancer SF295 Cells. Marine Drugs, 2014, 12, 4200-4213.	2.2	47
54	Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription. Journal of Medicinal Chemistry, 2016, 59, 3650-3660.	2.9	47

#	Article	IF	Citations
55	Development and Characterization of a Model of Liver Metastasis Using Human Colon Cancer HCT-116 Cells. Biological and Pharmaceutical Bulletin, 2007, 30, 1779-1783.	0.6	44
56	Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochemical and Biophysical Research Communications, 2009, 379, 104-109.	1.0	44
57	Inhibition of spontaneous and experimental tumor metastasis by the calcium antagonist verapamil. Cancer Chemotherapy and Pharmacology, 1985, 14, 30-33.	1.1	43
58	Sequence Specificity, Reactivity, and Antitumor Activity of DNA-Alkylating Pyrrole-Imidazole Diamides. Chemistry and Biology, 2003, 10, 751-758.	6.2	43
59	Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer, 2010, 70, 94-102.	0.9	43
60	Isolation and structures of biselyngbyasides B, C, and D from the marine cyanobacterium Lyngbya sp., and the biological activities of biselyngbyasides. Tetrahedron, 2012, 68, 5984-5990.	1.0	42
61	Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. Scientific Reports, 2017, 7, 3605.	1.6	40
62	Repression of Cyclin B1 Expression after Treatment with Adriamycin, but Not Cisplatin in Human Lung Cancer A549 Cells. Biochemical and Biophysical Research Communications, 2001, 280, 861-867.	1.0	39
63	Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles. Metallomics, 2013, 5, 461.	1.0	39
64	Tumor-induced platelet aggregation and growth promoting factors as determinants for successful tumor metastasis. Clinical and Experimental Metastasis, 1986, 4, 25-33.	1.7	38
65	Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1347-1349.	1.0	38
66	Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions. Biochemical and Biophysical Research Communications, 2010, 392, 460-466.	1.0	38
67	New Biologically Active Marine Sesquiterpenoid and Steroid from the Okinawan Sponge of the Genus Axinyssa.. Chemical and Pharmaceutical Bulletin, 2002, 50, 1286-1289.	0.6	37
68	YM-216391, a Novel Cytotoxic Cyclic Peptide from Streptomyces nobilis. Journal of Antibiotics, 2005, 58, 27-31.	1.0	37
69	Synthesis and Biological Evaluation of Boronic Acid Containingcis-Stilbenes as Apoptotic Tubulin Polymerization Inhibitors. ChemMedChem, 2006, 1, 729-740.	1.6	37
70	Evaluation of Action Mechanisms of Toxic Chemicals Using JFCR39, a Panel of Human Cancer Cell Lines. Molecular Pharmacology, 2007, 72, 1171-1180.	1.0	37
71	Expression of Sulfomucins in Normal Mucosae, Colorectal Adenocarcinomas and Metastases. Japanese Journal of Cancer Research, 1995, 86, 1060-1067.	1.7	36
72	Î²-Hydroxyisovalerylshikonin Is a Novel and Potent Inhibitor of Protein Tyrosine Kinases. Japanese Journal of Cancer Research, 2002, 93, 944-951.	1.7	36

#	Article	IF	Citations
73	Synthesis of Functional Proteins by Mixing Peptide Motifs. Chemistry and Biology, 2004, 11, 765-773.	6.2	36
74	ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo. European Journal of Cancer, 2012, 48, 936-943.	1.3	36
75	Glaziovianin A, a new isoflavone, from the leaves of Ateleia glazioviana and its cytotoxic activity against human cancer cells. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3091-3094.	1.0	34
76	The relationship of collagenolytic activity to stage of human colorectal carcinoma. International Journal of Cancer, 1987, 40, 24-31.	2.3	33
77	Total Synthesis of Murisolins and Evaluation of Tumor-Growth Inhibitory Activity. Chemistry - A European Journal, 2005, 11, 6237-6245.	1.7	33
78	Synthesis of hybrid acetogenins, Î±,Î²-unsaturated-Î³-lactone-free nitrogen-containing heterocyclic analogues, and their cytotoxicity against human cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1637-1641.	1.0	33
79	Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. Arthritis Research and Therapy, 2010, 12, R92.	1.6	33
80	Growth stimulating activity of lung extract on lung-colonizing colon 26 clones and its partial characterization. Clinical and Experimental Metastasis, 1988, 6, 131-139.	1.7	32
81	Antitumor effect of cotylenin A plus interferon-Î±: Possible therapeutic agents against ovary carcinoma. Gynecologic Oncology, 2005, 99, 680-688.	0.6	32
82	Thiophene-3-carboxamide analogue of annonaceous acetogenins as antitumor drug lead. European Journal of Medicinal Chemistry, 2014, 86, 684-689.	2.6	31
83	Antitumor activity, optimum administration method and pharmacokinetics of 13,14-dihydro-15-deoxy-Î7-prostaglandin A1 methyl ester (TEI-9826) integrated in lipid microspheres (Lipo) Tj ETQq1 1 0.784314 rgBT /(	1.7	30
84	Isolation of Peridinin-Related Norcarotenoids with Cell Growth-Inhibitory Activity from the Cultured Dinoflagellate of Symbiodinium sp., a Symbiont of the Okinawan Soft Coral Clavularia viridis, and Analysis of Fatty Acids of the Dinoflagellate. Chemical and Pharmaceutical Bulletin, 2003, 51, 724-727.	0.6	30
85	Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants. Bioorganic and Medicinal Chemistry, 2012, 20, 3887-3897.	1.4	29
86	Synthesis and Preclinical Evaluations of 2-(2-Fluorophenyl)-6,7-methylenedioxyquinolin-4-one Monosodium Phosphate (CHM-1â^'P-Na) as a Potent Antitumor Agent. Journal of Medicinal Chemistry, 2010, 53, 1616-1626.	2.9	28
87	Inhibitory Activity of Flavonoids against Class I Phosphatidylinositol 3-Kinase Isoforms. Molecules, 2011, 16, 5159-5167.	1.7	27
88	Production of Biologically Active Taxoids by a Callus Culture ofTaxus cuspidata. Journal of Natural Products, 2004, 67, 58-63.	1.5	26
89	Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents. Biochemical Pharmacology, 2008, 75, 1014-1026.	2.0	26
90	Identification of Chrysoplenetin from Vitex negundo as a Potential Cytotoxic Agent against PANCâ€1 and a Panel of 39 Human Cancer Cell Lines (JFCRâ€39). Phytotherapy Research, 2011, 25, 1770-1775.	2.8	26

#	Article	IF	Citations
91	Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities. European Journal of Medicinal Chemistry, 2013, 60, 295-304.	2.6	25
92	Total Synthesis of AMF-26, an Antitumor Agent for Inhibition of the Golgi System, Targeting ADP-Ribosylation Factor 1. Journal of Medicinal Chemistry, 2013, 56, 150-159.	2.9	25
93	Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors. European Journal of Medicinal Chemistry, 2016, 121, 592-609.	2.6	25
94	Pyrrocidine A, a metabolite of endophytic fungi, has a potent apoptosis-inducing activity against HL60 cells through caspase activation via the Michael addition. Journal of Antibiotics, 2016, 69, 133-140.	1.0	25
95	Family-wide Analysis of the Inhibition of Arf Guanine Nucleotide Exchange Factors with Small Molecules: Evidence of Unique Inhibitory Profiles. Biochemistry, 2017, 56, 5125-5133.	1.2	25
96	Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. Oncotarget, 2018, 9, 1641-1655.	0.8	25
97	Control of Apoptosis and Growth of Malignant T Lymphoma Cells by Lymph Node Stromal Cells. Experimental Cell Research, 1993, 207, 271-276.	1.2	24
98	A novel thiopheneâ€3â€carboxamide analog of annonaceous acetogenin exhibits antitumor activity via inhibition of mitochondrial complex I. Pharmacology Research and Perspectives, 2016, 4, e00246.	1.1	24
99	Candicanoside A, a Novel Cytotoxic Rearranged Cholestane Glycoside from Galtonia candicans. Helvetica Chimica Acta, 2000, 83, 2698-2704.	1.0	23
100	New Bisindole Alkaloids Isolated from Myxomycetes Arcyria cinerea and Lycogala epidendrum. Chemical and Pharmaceutical Bulletin, 2005, 53, 594-597.	0.6	23
101	Identification of Transporters Associated with Etoposide Sensitivity of Stomach Cancer Cell Lines and Methotrexate Sensitivity of Breast Cancer Cell Lines by Quantitative Targeted Absolute Proteomics. Molecular Pharmacology, 2013, 83, 490-500.	1.0	23
102	Design, synthesis, and in vitro cancer cell growth inhibition evaluation and antimalarial testing of trioxanes installed in cyclic 2-enoate substructures. European Journal of Medicinal Chemistry, 2013, 69, 294-309.	2.6	23
103	Biselyngbyasides, cytotoxic marine macrolides, are novel and potent inhibitors of the Ca²⁺ pumps with a unique mode of binding. FEBS Letters, 2015, 589, 1406-1411.	1.3	23
104	In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. Investigational New Drugs, 2014, 32, 1134-1143.	1.2	22
105	M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers. Cancer Research, 2016, 76, 3895-3903.	0.4	22
106	Enantioselective Total Synthesis of (+)â€Ottelione A, (â^')â€Ottelione B, (+)â€3â€epiâ€Ottelione A and Preliminary Evaluation of Their Antitumor Activity. Chemistry - A European Journal, 2007, 13, 9866-9881.	1.7	21
107	Synthesis and biological activity of furanylindazoles as inhibitors of hypoxia inducible factor (HIF)-1 transcriptional activity. MedChemComm, 2012, 3, 1455.	3.5	21
108	Galtonioside A, a novel cytotoxic cholestane glycoside from Galtonia candicans. Tetrahedron Letters, 2000, 41, 251-255.	0.7	20

#	Article	IF	Citations
109	Spiromarienonols A and B: Two New 7(8â†'9)abeo-Lanostane-Type Triterpene Lactones from the Stem Bark ofAbies mariesii. Helvetica Chimica Acta, 2004, 87, 240-249.	1.0	20
110	Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer. Biochemical and Biophysical Research Communications, 2007, 352, 514-521.	1.0	20
111	Structureâ€"activity relationships of hybrid annonaceous acetogenins: Powerful growth inhibitory effects of their connecting groups between heterocycle and hydrophobic carbon chain bearing THF ring on human cancer cell lines. European Journal of Medicinal Chemistry, 2013, 63, 833-839.	2.6	19
112	Stromal Cells Positively and Negatively Modulate the Growth of Cancer Cells: Stimulation via the PGE2-TNFÎ±-IL-6 Pathway and Inhibition via Secreted GAPDH-E-Cadherin Interaction. PLoS ONE, 2015, 10, e0119415.	1.1	19
113	Discovery of Phosphatidylinositol 3-Kinase Inhibitory Compounds from the Screening Committee of Anticancer Drugs (SCADS) Library. Biological and Pharmaceutical Bulletin, 2010, 33, 1600-1604.	0.6	18
114	Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models. Molecular Cancer Therapeutics, 2010, 9, 3315-3321.	1.9	18
115	Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats. Inflammation Research, 2012, 61, 551-562.	1.6	18
116	Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation. Cancer Science, 2015, 106, 909-920.	1.7	18
117	Correlation between Cytotoxic Activities and Reduction Potentials of Heterocyclic Quinones. Molecules, 2010, 15, 6559-6569.	1.7	17
118	Establishment of phosphatidylinositol 3â€kinase inhibitorâ€resistant cancer cell lines and therapeutic strategies for overcoming the resistance. Cancer Science, 2012, 103, 1955-1960.	1.7	17
119	Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells. Scientific Reports, 2018, 8, 14827.	1.6	17
120	Enhanced cytocidal action of methotrexate by conjugation to concanavalin A. International Journal of Cancer, 1980, 26, 655-659.	2.3	16
121	Up-regulation of p27Kip1Correlates Inversely with Anchorage-independent Growth of Human Cancer Cell Lines. Japanese Journal of Cancer Research, 1998, 89, 110-115.	1.7	16
122	Cytotoxic dimeric sesquiterpenoids from Curcuma parviflora: isolation of three new parviflorenes and absolute stereochemistry of parviflorenes A, B, D, F, and G. Tetrahedron, 2005, 61, 6700-6706.	1.0	16
123	Marine Diterpenoids with a Briarane Skeleton from the Okinawan Soft Coral Pachyclavularia violacea. Chemical and Pharmaceutical Bulletin, 2007, 55, 1671-1676.	0.6	16
124	Synthesis of C4-fluorinated solamins and their growth inhibitory activity against human cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6451-6453.	1.0	15
125	Design and synthesis of C35-fluorinated solamins and their growth inhibitory activities against human cancer cell lines. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5745-5749.	1.0	15
126	Total synthesis of burkholdacs A and B and 5,6,20-tri-epi-burkholdac A: HDAC inhibition and antiproliferative activity. European Journal of Medicinal Chemistry, 2014, 76, 301-313.	2.6	15

#	Article	IF	Citations
127	Synthesis of dansyl-labeled probe of thiophene analogue of annonaceous acetogenins for visualization of cell distribution and growth inhibitory activity toward human cancer cell lines. Bioorganic and Medicinal Chemistry, 2015, 23, 1276-1283.	1.4	15
128	Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. Cancer Science, 2003, 94, 1074-1082.	1.7	14
129	Convergent synthesis of fluorescence-labeled probes of Annonaceous acetogenins and visualization of their cell distribution. Bioorganic and Medicinal Chemistry, 2010, 18, 8630-8641.	1.4	14
130	Novel tamoxifen derivative Ridaifen-B induces Bcl-2 independent autophagy without estrogen receptor involvement. Biochemical and Biophysical Research Communications, 2013, 435, 657-663.	1.0	14
131	A new evaluation method for quantifying PI3K activity by HTRF assay. Biochemical and Biophysical Research Communications, 2008, 377, 941-945.	1.0	13
132	Identification of a molecular target of kurahyne, an apoptosis-inducing lipopeptide from marine cyanobacterial assemblages. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5295-5298.	1.0	13
133	Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer Science, 2021, 112, 1963-1974.	1.7	13
134	Increased content of chondroitin sulfate proteoglycan in human colorectal carcinoma metastases compared with the primary tumor as determined by an anti-chondroitin-sulfate monoclonal antibody. Journal of Cellular Biochemistry, 1988, 36, 405-416.	1.2	12
135	New Dolabellane-Type Diterpenoids from the Okinawan Soft Coral of the GenusClavularia. Bulletin of the Chemical Society of Japan, 2002, 75, 131-136.	2.0	12
136	Synthesis and structureâ€“activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3722-3728.	1.0	12
137	Basal expression of insulinâ€like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3â€kinase inhibitor ZSTK474. Cancer Science, 2015, 106, 171-178.	1.7	12
138	Inhibition of DNA Topoisomerases II and/or I by Pyrazolo[1,5-a]indole Derivatives and Their Growth Inhibitory Activities. Molecular Pharmacology, 2002, 62, 873-880.	1.0	11
139	Discovery of ortho-Carborane-Conjugated Triazines as Selective Topoisomerase I/II Inhibitors. Australian Journal of Chemistry, 2011, 64, 1430.	0.5	11
140	Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway. Biochemical Pharmacology, 2013, 86, 1272-1284.	2.0	11
141	Search for Novel Anti-tumor Agents from Ridaifens Using JFCR39, a Panel of Human Cancer Cell Lines. Biological and Pharmaceutical Bulletin, 2013, 36, 1008-1016.	0.6	11
142	Synthesis and in vitro cancer cell growth inhibition evaluation of 11-amino-modified 5-Me-indolo[2,3-b]quinolines and their COMPARE analyses. Medicinal Chemistry Research, 2016, 25, 879-892.	1.1	11
143	The polar neutral and basic taxoids isolated from needles and twigs of Taxus cuspidata and their biological activity. Journal of Wood Science, 2008, 54, 390-401.	0.9	10
144	Convergent synthesis of stereoisomers of THF ring moiety of acetogenin thiophene analogue and their antiproliferative activities against human cancer cell lines. Tetrahedron, 2017, 73, 2359-2366.	1.0	10

#	Article	IF	Citations
145	A novel method for analyzing phosphoproteins using SELDI-TOF MS in combination with a series of recombinant proteins. Proteomics, 2007, 7, 2350-2354.	1.3	9
146	Motifâ€programmed artificial protein induces apoptosis in several cancer cells by disrupting mitochondria. Cancer Science, 2008, 99, 398-406.	1.7	9
147	Effectiveness of combined treatment using Xâ€rays and a phosphoinositide 3â€kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo. Cancer Science, 2011, 102, 1176-1180.	1.7	9
148	Development of a gene expression database and related analysis programs for evaluation of anticancer compounds. Cancer Science, 2013, 104, 360-368.	1.7	9
149	Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines. Oncotarget, 2018, 9, 35141-35161.	0.8	9
150	Mâ€<scp>COPA</scp>, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin. Genes To Cells, 2016, 21, 901-906.	0.5	8
151	A Potential Role of Adhesion Molecules on Lung Metastasis Enhanced by Local Inflammation. Anticancer Research, 2020, 40, 6171-6178.	0.5	8
152	Isolation of a Novel Gene Showing Reduced Expression in Metastatic Colorectal Carcinoma Cell Lines and Carcinomas. Japanese Journal of Cancer Research, 1997, 88, 725-731.	1.7	7
153	Application of In Vivo ESR/Spin-Probe Technique to Monitor Tumor In Vivo in Mouse Footpad. Antioxidants and Redox Signaling, 2007, 9, 1699-1708.	2.5	7
154	Identification of Candidate Genes Determining Chemosensitivity to Anti-cancer Drugs of Gastric Cancer Cell Lines. Biological and Pharmaceutical Bulletin, 2009, 32, 1936-1939.	0.6	7
155	Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics. International Journal of Clinical Oncology, 2015, 20, 490-498.	1.0	7
156	Absolute Quantification of Four Isoforms of the Class I Phosphoinositide-3-kinase Catalytic Subunit by Real-Time RT-PCR. Biological and Pharmaceutical Bulletin, 2007, 30, 1181-1184.	0.6	6
157	Alkyl isothiocyanates suppress epidermal growth factor receptor kinase activity but augment tyrosine kinase activity. Cancer Epidemiology, 2009, 33, 288-292.	0.8	6
158	Ridaifen G, tamoxifen analog, is a potent anticancer drug working through a combinatorial association with multiple cellular factors. Bioorganic and Medicinal Chemistry, 2015, 23, 6118-6124.	1.4	6
159	Establishment of a Hepatocyte Cell Line Producing Growth-promoting Factors for Liver-colonizing Tumor Cells. Japanese Journal of Cancer Research, 1996, 87, 146-152.	1.7	4
160	Potent Antitumor Activity of 3,4-seco-8Î²H-Ferna-4(23),9(11)-dien-3-oic Acid (EC-2) and 3,4-seco-Oleana-4(23),18-dien-3-oic Acid (EC-4), Evaluated by an in vitro Human Cancer Cell Line Panel. Planta Medica, 2006, 72, 1347-1349.	0.7	4
161	Development of an Immunohistochemical Protein Quantification System in Conjunction with Tissue Microarray Technology for Identifying Predictive Biomarkers for Phosphatidylinositol 3-Kinase Inhibitors. Biological and Pharmaceutical Bulletin, 2012, 35, 1607-1613.	0.6	4
162	Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MS. Proteome Science, 2009, 7, 14.	0.7	3

#	Article	IF	Citations
163	Total Synthesis of the Depsipeptide FR901375 and Preliminary Evaluation of Its Biological Activity. European Journal of Organic Chemistry, 2016, 2016, 5667-5677.	1.2	3
164	A Potential Mechanism of Tumor Progression during Systemic Infections Via the Hepatocyte Growth Factor (HGF)/c-Met Signaling Pathway. Journal of Clinical Medicine, 2020, 9, 2074.	1.0	3
165	Screening with COMPARE Analysis for Telomerase Inhibitors. , 2002, 191, 197-208.		2
166	Discovery of Inhibitors of Membrane Traffic from a Panel of Clinically Effective Anticancer Drugs. Biological and Pharmaceutical Bulletin, 2019, 42, 814-818.	0.6	2
167	A Novel Differentiation Factor for PC12 Cells from Culture Supernatant of Mouse Hepatocyte Cell Line MLE-15A2. Bioscience, Biotechnology and Biochemistry, 1996, 60, 1339-1345.	0.6	1
168	Antibacterial and Antiproliferative Activity of Cationic Fullerene Derivatives.. ChemInform, 2004, 35, no.	0.1	0
169	[MOURNING] Memory of Dr.Tsukagoshi. Drug Delivery System, 2016, 31, 403-404.	0.0	0
170	Possible Contribution of Drug Approval Summaries Published by Drug Regulatory Authorities on Scientific Discussion and Drug Development. Clinical Pharmacology in Drug Development, 2020, 9, 6-10.	0.8	0